Lofexidine
- Generic Name
- Lofexidine
- Brand Names
- Lucemyra
- Drug Type
- Small Molecule
- Chemical Formula
- C11H12Cl2N2O
- CAS Number
- 31036-80-3
- Unique Ingredient Identifier
- UI82K0T627
- Background
Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was...
- Indication
Lofexidine is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment. It is the first non-opioid medication for the symptomatic management of opioid discontinuation.
...
- Associated Conditions
- Abrupt opioid withdrawal
- Associated Therapies
- -
Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 52
- Registration Number
- NCT05569031
- Locations
- 🇪🇬
Faculty of medicine, Zagazig, Sharkia, Egypt
Evaluating Buspirone to Treat Opioid Withdrawal
- Conditions
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 100
- Registration Number
- NCT05511909
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Spark Biomedical, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT05053503
- Locations
- 🇺🇸
Hazelden Betty Ford Foundation, Plymouth, Minnesota, United States
🇺🇸Gaudenzia, Inc., Crownsville, Maryland, United States
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
- Conditions
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 60
- Registration Number
- NCT05027919
- Locations
- 🇺🇸
Johns Hopkins University Bayview Medical Campus, Baltimore, Maryland, United States
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 120
- Registration Number
- NCT04360681
- Locations
- 🇺🇸
South Texas Veterans Health Care System, San Antonio, Texas, United States
🇺🇸Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States
An Innovative Intervention for OUD Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 75
- Registration Number
- NCT04325659
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- USWM, LLC (dba US WorldMeds)
- Target Recruit Count
- 4
- Registration Number
- NCT04070157
- Locations
- 🇺🇸
Vitamed Research, Rancho Mirage, California, United States
🇺🇸Gold Coast Research, LLC, Plantation, Florida, United States
🇺🇸Duke Innovation Pain Therapies Clinic at Brier Creek, Raleigh, North Carolina, United States
Impact of Lofexidine on Stress, Craving and Opioid Use
- Conditions
- Interventions
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 112
- Registration Number
- NCT03718065
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- USWM, LLC (dba US WorldMeds)
- Target Recruit Count
- 24
- Registration Number
- NCT02681198
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Open-Label, Safety Study of Lofexidine
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- USWM, LLC (dba US WorldMeds)
- Target Recruit Count
- 286
- Registration Number
- NCT02363998
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.